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Abstract
Aims: The use of doxorubicin, a potent chemotherapeutic agent, is limited by cardiotoxicity. We tested the
hypothesis that decreased soluble guanylate cyclase (sGC) enzyme activity contributes to the development of
doxorubicin-induced cardiotoxicity.
Results: Doxorubicin administration (20mg/kg, intraperitoneally [IP]) reduced cardiac sGC activity in wild-type
(WT) mice. To investigate whether decreased sGC activity contributes to doxorubicin-induced cardiotoxicity, we
studied mice with cardiomyocyte-specific deficiency of the sGC a1-subunit (mice with cardiomyocyte-specific
deletion of exon 6 of the sGCa1 allele [sGCa1-/-CM]). After 12weeks of doxorubicin administration (2mg/kg/week
IP), left ventricular (LV) systolic dysfunction was greater in sGCa1-/-CM than WTmice. To further assess whether
reduced sGC activity plays a pathogenic role in doxorubicin-induced cardiotoxicity, we studied a mouse model in
which decreased cardiac sGC activity was induced by cardiomyocyte-specific expression of a dominant negative
sGCa1 mutant (DNsGCa1) upon doxycycline removal (Tet-off). After 8 weeks of doxorubicin administration,
DNsGCa1tg/+, but not WT, mice displayed LV systolic dysfunction and dilatation. The difference in cardiac
function and remodeling between DNsGCa1tg/+ and WT mice was even more pronounced after 12 weeks of
treatment. Further impairment of cardiac function was attenuated when DNsGCa1 gene expression was
inhibited (beginning at 8 weeks of doxorubicin treatment) by administering doxycycline. Furthermore,
doxorubicin-associated reactive oxygen species generation was higher in sGCa1-deficient than WT hearts.
Innovation and Conclusion: These data demonstrate that a reduction in cardiac sGC activity worsens
doxorubicin-induced cardiotoxicity in mice and identify sGC as a potential therapeutic target. Various phar-
macological sGC agonists are in clinical development or use and may represent a promising approach to limit
doxorubicin-associated cardiotoxicity. Antioxid. Redox Signal. 26, 153–164.
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Introduction
S ince its discovery more than five decades ago, theanthracycline, doxorubicin, has become a central com-
ponent of therapeutic regimens to treat various malignancies,
including lymphoma, sarcoma, some leukemias, and breast
cancer. Unfortunately, the clinical use of this potent che-
motherapeutic agent is hampered by cardiotoxicity. The early
adverse cardiac effects of doxorubicin are often transient and
resolve spontaneously (18, 33, 37, 43). Of far greater concern
is the development of chronic cardiomyopathy, leading to
symptomatic congestive heart failure in up to 5% of
doxorubicin-treated patients (8, 23, 46). In childhood cancer
survivors, the long-term risk of late-onset doxorubicin-
associated heart failure can be as high as 12% at the age of 40
(9). The most important risk factor for the development of
doxorubicin-induced cardiomyopathy is the cumulative dose.
Although various pathogenic mechanisms have been
suggested to underlie doxorubicin-induced cardiotoxicity,
many studies support a pivotal role of oxidative stress (11, 22,
30, 32, 50, 56). Cardiomyocytes are particularly prone to
damage by free radicals because of the high oxidative me-
tabolism, low concentrations of antioxidant enzymes, and
abundance of mitochondria (14, 15).
With a univalent redox potential of approximately -320mV,
doxorubicin is a good substrate for intracellular oxidoreduc-
tases such as xanthine oxidase, NADPH cytochrome P450 re-
ductase, and NADH dehydrogenase (12–14, 49). Reduction
of the quinone moiety of doxorubicin results in an unstable
semiquinone radical that donates an electron to molecular
oxygen, thereby forming superoxide radicals. If free iron is
present, the semiquinone radical can also form a complex
with iron, resulting in an anthracycline–iron free radical
complex that in turn reduces molecular oxygen (31).
Dexrazoxane (ICRF-187), the only drug currently in
clinical use to protect against doxorubicin-induced cardio-
toxicity, is thought to confer cardioprotection by chelating
iron and subsequently reducing anthracycline–iron free rad-
ical complex formation and superoxide radicals (21). Because
of reports of lower tumor responsiveness or enhanced myelo-
suppression in chemotherapy-receiving patients treated with
dexrazoxane, the US Food and Drug Administration and the
European Medicines Agency restricted the use of dexrazox-
ane (38, 47). Although a growing body of literature suggests
that dexrazoxane does not adversely affect therapeutic re-
sponse (28, 40, 41, 53), additional mechanism-based therapies
for doxorubicin-induced cardiotoxicity are needed.
The second messenger cyclic guanosine 3¢,5¢-mono-
phosphate (cGMP) regulates a vast array of physiological
processes vital to endothelial, vascular smooth muscle, and
cardiomyocyte function. cGMP is generated by particulate
guanylate cyclase in response to natriuretic peptides and by
soluble guanylate cyclase (sGC) upon activation by nitric
oxide (NO) and, less potently, carbon monoxide (CO). Dis-
ruption of the cGMP signaling pathway has been implicated
in adverse cardiac remodeling and heart failure. Interestingly,
doxorubicin administration reduced cardiac cGMP levels,
which could be prevented by inhalation of CO (45).
In this study, we investigated the role of sGC in doxorubicin-
induced cardiotoxicity. We observed that doxorubicin admin-
istration decreased cardiac sGC activity and that reduced sGC
activity exacerbated reactive oxygen species (ROS) formation
in the heart and development of doxorubicin-induced cardiac
dysfunction.
Results
Doxorubicin administration reduces cardiac
sGC activity
To examine the effect of doxorubicin treatment on sGC
enzymatic activity in the heart, the increase in cGMP produc-
tion induced by the NO donor diethylenetriamine NONOate
(DETA-NO) was measured in cardiac extracts from wild-type
(WT) mice 24h after doxorubicin (20mg/kg, intraperitoneally
[IP]) or saline administration. Doxorubicin treatment reduced
cardiac NO-stimulated sGC activity by*20% (Fig. 1A).
sGC is a heterodimeric enzyme comprising a b1 subunit
and either an a1 or a2 subunit, with the sGCa1b1 isoform
being the predominant isoform in the heart (6). Immunoblot
analysis did not reveal changes in sGCa1 or sGCb1 protein
expression in hearts of doxorubicin-treated mice (Supple-
mentary Fig. S1; Supplementary Data are available online at
www.liebertpub.com/ars), indicating that the doxorubicin-
induced decrease in cardiac sGC activity is not due to altered
sGC expression.
It is conceivable that the oxidative stress associated with
doxorubicin administration results in direct oxidative modifi-
cation of sGC, potentially leading to loss of its prosthetic heme
moiety (2, 4, 26, 42, 48) and decreased enzyme activity. To
explore this possibility, we administered the radical scavenger
tempol to WT mice before treatment with doxorubicin (20mg/
kg, IP) or saline and evaluated cardiac sGC activity in the
presence of DETA-NO. Tempol administration prevented the
doxorubicin-induced decrease in cardiac NO-stimulated sGC
activity (Fig. 1B), suggesting that this decrease in activity is due
to oxidative modification of sGC.
Our hypothesis that doxorubicin treatment results in oxida-
tion of sGC was further corroborated by the observation that
BAY 58-2667 (cinaciguat), an sGC agonist specifically tar-
geting oxidized and heme-free sGC (42), increased sGC ac-
tivity in cardiac extracts obtained from doxorubicin- and saline-
treatedWTmice to the same extent (Fig. 1C). Thus, whereas in
hearts of doxorubicin-treated mice, activation of sGC by NO—
requiring the heme group of sGC to be in a reduced state—was
impaired, sGC activation by BAY 58-2667 was not.
Innovation
Adverse effects observed in chemotherapy patients re-
ceiving dexrazoxane, the only drug approved to attenuate
doxorubicin-induced cardiotoxicity in patients, have re-
stricted its use. This study illustrates that doxorubicin re-
duces cardiac soluble guanylate cyclase (sGC) activity and
that reduced sGC activity exacerbates doxorubicin-induced
cardiotoxicity. Increasing interest in sGC as a therapeutic
target is driving clinical development of pharmacological
sGC agonists, and the first drug in this class was recently
approved to treat pulmonary hypertension. Because our
data suggest that sGC protects against doxorubicin-induced
cardiotoxicity, pharmacological sGC agonists could repre-
sent a novel therapeutic strategy to treat cardiotoxicity in
patients undergoing chemotherapy.
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Constitutive myocardial sGCa1 deficiency exacerbates
doxorubicin-induced cardiac dysfunction
To evaluate whether the doxorubicin-induced decrease in
sGC activity contributes to the development of cardiotoxi-
city, we studied mice with cardiomyocyte-specific reduction
of sGC activity (sGCa1-/-CM). Cre-mediated deletion of exon
6 of sGCa1 in cardiomyocytes attenuated the ability of
DETA-NO to activate sGC in the heart: the relative fold
increase in cGMP synthesis was 0.64 – 0.09 versus
1.00 – 0.18 in sGCa1-/-CM andWTmice, respectively (n= 10
and 8, p< 0.05). Restriction of sGCa1 deficiency to the heart
in sGCa1-/-CM mice was confirmed by polymerase chain
reaction (PCR) analysis (Supplementary Fig. S2). Baseline
echocardiographic parameters, including left ventricular
(LV) end-systolic and end-diastolic internal diameters and
fractional shortening (FS), were similar in sGCa1-/-CM mice
and WT littermates (Supplementary Table S1).
Cardiotoxicity was induced in sGCa1-/-CM and WT mice
(n = 14 for both) by administering doxorubicin (2mg/kg IP,
once weekly) for 12 weeks, as previously reported (51).
Following 8 weeks of doxorubicin administration, echocar-
diography revealed that end-systolic internal diameter
(LVIDES) was increased (Fig. 2A) and FS decreased (Fig. 2B)
in both sGCa1-/-CM and WT mice compared with baseline
measurements obtained before the first doxorubicin injection.
However, after 12 weeks, doxorubicin-induced systolic
dysfunction was significantly greater in sGCa1-/-CM mice than
inWT littermates: LVIDES was greater (Fig. 2A) and FS lower
(Fig. 2B) in sGCa1-/-CM than in WT mice. In addition, com-
pared with baseline, LV end-diastolic internal diameter (LVI-
DED) was modestly increased after 12 weeks of doxorubicin
treatment in sGCa1-/-CM mice (3.3– 0.04 vs. 3.1– 0.03mm,
respectively, p< 0.05), but not in WT mice (3.2– 0.05 vs.
3.1– 0.03mm, p> 0.05). Invasive LV pressure–volume mea-
surements confirmed more pronounced systolic dysfunc-
tion, as evidenced by the reduced ejection fraction (EF), in
doxorubicin-treated sGCa1-/-CM versus WT mice (Table 1).
Similar to previous reports (10, 35, 36), doxorubicin ad-
ministration in mice was associated with a decrease in heart
rate (HR), assessed via invasive hemodynamic measurements
(Table 1) and echocardiography (sGCa1-/-CM + doxorubicin
vs. sGCa1-/-CM + saline; 426– 18 vs. 505– 18 beats per minute
[bpm] and WT + doxorubicin vs. WT + saline; 428– 17 vs.
531– 13 bpm, p< 0.05 for doxorubicin vs. saline in both ge-
notypes). HR did not differ between doxorubicin-treated
sGCa1-/-CM and WT mice ( p> 0.05).
Furthermore, doxorubicin administration reduced survival
rates to a similar extent in sGCa1-/-CM and WT mice (71%
vs. 86%, respectively, n = 14 for both, p> 0.05), as well as
body weights (-23 – 3% vs. -19 – 2%, respectively, n = 10
and 12, p > 0.05).
Doxorubicin-associated cardiotoxicity is increased
in mice with inducible cardiomyocyte-specific
expression of a dominant negative sGCa1 mutant
To further assess whether reduced sGC activity plays a
pathogenic role in doxorubicin-induced cardiotoxicity, a
second mouse model with inducible cardiomyocyte-specific
sGCa1 deficiency was generated and studied. Upon with-
drawal of doxycycline from the diet, a dominant negative
sGCa1 mutant (DNsGCa1, Tet-Off system) is expressed that
competes with sGCa1 and sGCa2 for binding to sGCb1,
thereby inhibiting the formation of the two catalytically ac-
tive sGC heterodimers in the heart.
Four weeks after doxycycline removal from the diet, the
ability of DETA-NO to activate sGC was attenuated in the
FIG. 1. Cardiac NO-stimulated
sGC activity is decreased in mice
treated with DOX. (A) NO-
stimulated sGC activity was lower
in cardiac extracts from mice trea-
ted with DOX (20mg/kg IP, 24 h)
than from mice administered saline
(n = 10 each). (B) Tempol admin-
istration before DOX or saline
treatment prevented this decrease
in cardiac NO-stimulated sGC ac-
tivity (n = 9 and 8, respectively).
(C) In addition, incubation with the
sGC activator, BAY 58-2667, in-
creased sGC activity in the cardiac
extracts obtained from DOX- and
saline-treated mice to the same
extent (n = 10 each). Data are ex-
pressed relative to sGC activity in
the contemporaneous saline-treated
control group. *p < 0.05 versus sa-
line. DOX, doxorubicin; IP, intra-
peritoneal; NO, nitric oxide; sGC,
soluble guanylate cyclase.
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hearts of mice with cardiomyocyte-specific expression of a
dominant negative mutation of sGCa1 (DNsGCa1tg/+) mice:
the relative fold increase in cGMP synthesis was 0.59– 0.07
versus 1.00– 0.11 in DNsGCa1tg/+ and WT mice, respectively
(n= 8 each, p< 0.05). Baseline echocardiographic parameters
were similar in DNsGCa1tg/+ mice and WT littermates (Sup-
plementary Table S2).
After 8 weeks of doxorubicin treatment (2mg/kg IP, once
weekly), systolic dysfunction and dilatation, characterized by
increased LVIDES and LVIDED (Fig. 3A, B) and decreased
FS (Fig. 3C), were apparent in DNsGCa1tg/+ mice, but not
WT mice. After 12 weeks of doxorubicin treatment, LV
functional impairment and dilatation had further progressed
in DNsGCa1tg/+ mice. Overall, these data are consistent with
the greater doxorubicin-induced systolic dysfunction ob-
served in sGCa1-/-CM mice and suggest that sGC may protect
against cardiac dysfunction associated with chronic doxorubi-
cin treatment.
Of note, treating mice with doxorubicin for 12 weeks de-
creased survival rates to a similar extent in DNsGCa1tg/+ and
WT mice (67% vs. 56%, respectively, n = 30 and 34,
p > 0.05), as well as body weights (-12– 0% vs. -15 – 1%,
respectively, n = 18 and 17, p> 0.05).
Doxorubicin-induced cardiotoxicity in mice
with induced expression of mutated sGCa1
is attenuated by reversal of sGCa1 mutant expression
The observation that systolic dysfunction occurs within 8
weeks of doxorubicin treatment in DNsGCa1tg/+, but not WT,
mice provided a model to test the therapeutic potential of re-
moving sGC activity inhibition by readministering doxycy-
cline. DNsGCa1tg/+ andWTmicewere exposed to doxorubicin
for 12 weeks (2mg/kg IP, once weekly), and after 8 weeks of
doxorubicin treatment, doxycycline was added to the diet of
both DNsGCa1tg/+ and WT mice for an additional 8 weeks,
restoring cardiac sGC activity in DNsGCa1tg/+mice (Fig. 4A).
Cardiac functionwas assessed by echocardiography after 12
weeks of doxorubicin administration (T12 weeks) and 4 weeks
later (T16 weeks). After 12 weeks of doxorubicin treatment,
including 4 weeks of doxycycline administration, cardiac
dysfunction and dilatation were still more pronounced in
DNsGCa1tg/+ than in WT mice (Fig. 4B). However, 4 weeks
later, functional deterioration and adverse remodeling had
progressed further in WT mice, whereas cardiac dysfunction
and dilatation were reduced in DNsGCa1tg/+ mice (Fig. 4B).
These findings suggest that restoring sGC activity can atten-
uate doxorubicin-induced LV dysfunction in mice.
Morphological changes associated with doxorubicin
administration were similar in DNsGCa1tg/+
and WT hearts
To assess potential differences in the degree of doxorubicin-
induced cardiac atrophy between sGCa1-deficientmice andWT
mice, we measured heart weights in both genotypes following
12 weeks of doxorubicin or saline administration. Doxorubicin
treatment decreased normalized heart weight by 18% and 24%
in sGCa1-/-CM and WT mice, respectively, compared with
saline-treated controls (Supplementary Table S3, p>0.05).
Similarly, in doxorubicin-treated DNsGCa1tg/+ and WT mice,
heart weight was decreased by 17% and 15%, respectively,
compared with saline-treated mice (Supplementary Table S3,
p>0.05).
To further explore the mechanisms underlying the differ-
ence in doxorubicin-induced cardiac dysfunction between
sGCa1-deficient mice and WT mice, we examined fibrosis,
apoptosis, inflammation, and vascular density in hearts of
DNsGCa1tg/+ and WT mice following 12 weeks of doxoru-
bicin administration.
To investigate cardiac fibrosis, we measured collagen de-
position and expression levels of two key mediators of fi-
brosis: transforming growth factor (TGF)-b1 and connective
tissue growth factor (CTGF). CTGF is the profibrotic medi-
ator through which TGF-b1 triggers connective tissue cell
proliferation, adhesion, migration, and the synthesis of ex-
tracellular matrix. Analysis of Sirius red-stained tissue sections
using circularly polarized light revealed comparable deposition
of thick, tightly packed, red birefringent collagen fibers as well
as thin, loosely assembled, green birefringent collagen fibers in
the two genotypes (Supplementary Table S4). Consistent with
these results, TGF-b1 and CTGF transcript levels were similar
in doxorubicin-treated DNsGCa1tg/+ and WT mice (Supple-
mentary Table S4).
In addition, the number of apoptotic cardiomyocytes was
similar in DNsGCa1tg/+ and WT mice after 12 weeks of doxo-
rubicin treatment. In accordance with these results, cardiac
FIG. 2. Greater systolic dysfunction in sGCa1-/-CM
than WT mice after 12 weeks of DOX treatment. Echo-
cardiographic analysis revealed decreased LV systolic
function in sGCa1-/-CM and WT mice (n = 14 each) after 8
weeks of DOX administration, illustrated by an increased
LVIDES (A) and a reduced FS (B). After 12 weeks of DOX
treatment, systolic dysfunction was significantly greater in
sGCa1-/-CM than in WT mice. {p < 0.05 versus baseline and
*p < 0.05 versus WT (same time point). FS, fractional
shortening; LV, left ventricular; LVIDES, left ventricular
end-systolic internal diameter; sGCa1-/-CM, mice with
cardiomyocyte-specific deletion of exon 6 of the sGCa1
allele; WT, wild-type.
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mRNA expression levels of antiapoptotic B cell lymphoma 2
(Bcl-2) and proapoptotic Bcl-2-associated X protein (Bax) did
not differ between the two genotypes (Supplementary Table S4).
In addition, the number of infiltrated CD45-positive leu-
kocytes, a measure of cardiac inflammation, was similar in
hearts of DNsGCa1tg/+ and WT mice after 12 weeks of
doxorubicin administration (relative to the number of cardi-
omyocyte nuclei; Supplementary Table S4).
Furthermore, vascular density was comparable in
DNsGCa1tg/+ and WT hearts after 12 weeks doxorubicin
treatment (Supplementary Table S4), suggesting that a lower
density of capillaries, supplying cardiomyocytes with oxygen
and nutrients, did not contribute to the greater cardiac dys-
function in doxorubicin-treated DNsGCa1tg/+ mice.
Doxorubicin-induced ROS generation
is increased in sGCa1-deficient mice
To consider the possibility that doxorubicin induced higher
levels of oxidative stress in sGCa1-deficient than inWTmice,
we investigated the degree of doxorubicin-induced ROS
generation in cardiomyocytes isolated from sGCa1-deficient
and WT mice. sGCa1-/- and WT cardiomyocytes were ex-
posed to doxorubicin (50lM) for 3 h and then incubated with
chloromethyl derivate of 2¢,7¢-dichlorodihydrofluorescein
diacetate (CM-H2DCFDA). This cell-permeable compound is
deacetylated by intracellular esterases and then oxidized by
hydrogen peroxide (5) and other oxidants (20) to produce
fluorescent 2¢,7¢-dichlorofluorescein (DCF). Three hours after
exposure to doxorubicin, greater DCF fluorescence, and thus
ROS production, was observed in sGCa1-/- than in WT car-
diomyocytes (Fig. 5A).
Similarly, reactive nitrogen species-mediated tyrosine ni-
tration was more pronounced in sGCa1-/- than WT hearts 24 h
after doxorubicin administration (Fig. 5B). In addition, higher
expression of malondialdehyde (MDA) was observed in
DNsGCa1tg/+ than WT hearts after 12 weeks of doxorubicin
treatment (Fig. 5C). MDA is a product of lipid peroxidation,
frequently initiated by hydroxyl and hydroperoxyl radicals (3).
Taken together, these results suggest that doxorubicin-
induced oxidative stress is more pronounced when cardiac
sGC activity is reduced. This in turn could lead to enhanced
sGC oxidation and decrease in activity and subsequent ex-
acerbation of ROS levels via a yet to be identified negative
feedback system.
Discussion
The long-term adverse cardiac effects of doxorubicin,
which limit the use of this effective chemotherapeutic
agent, emphasize the need for novel therapeutic approaches
to prevent and treat cardiotoxicity associated with doxo-
rubicin treatment. Our data identify sGC as a potential
therapeutic target for doxorubicin-induced cardiotoxicity.
Twenty-four hours after doxorubicin administration, cardiac
sGC activity was reduced in mice. Since cardiac sGC expres-
sion was not altered by doxorubicin treatment, the observed
decrease in activity likely results from post-translational
modification of sGC.Oxidativemodification of sGC, leading to
loss of its prosthetic heme group and generation of NO-
insensitive sGC, was previously reported in cardiovascular
diseases associated with increased oxidative stress (2, 4, 26, 42,
48). In vivo administration of the radical scavenger, tempol, or
targeting oxidized and heme-free sGC by adding the sGC ac-
tivator, BAY 58-2667, ex vivo rescued the doxorubicin-
associated decrease in cardiac sGC activity, suggesting that
doxorubicin-induced oxidative modification of sGC represents
an underlying mechanism for the reduction in activity.
Table 1. Greater Systolic Dysfunction in sGCa1-/-CM than Wild-Type Mice After 12 Weeks
of Doxorubicin Administration
WT + saline
(n = 6)
sGCa1-/-CM + saline
(n = 5)
WT + DOX
(n= 12)
sGCa1-/-CM + DOX
(n = 9)
Adjusted
p-value
ESV (ll) 19 – 1 19– 1 26 – 3 37 – 3{,* 0.01
EDV (ll) 43 – 2 41– 2 51 – 2 58 – 2{ 0.07
EF (%) 60 – 2 58– 3 55 – 4 42 – 4* 0.03
MAP (mmHg) 104 – 5 96– 6 105 – 5 102 – 4 0.94
Ea (mmHg/ll) 3.6 – 0.3 3.6 – 0.4 4.0 – 0.4 3.9 – 0.3 1.00
PES (mmHg) 91 – 8 83– 4 97 – 4 91 – 5 0.67
PED (mmHg) 2.5 – 0.5 2.6 – 0.3 3.3 – 0.6 4.5 – 0.7{ 0.11
dP/dtmax (mmHg/s) 13,499 – 1433 11,995– 601 13,503 – 678 10,387 – 922* 0.03
dP/dtmin (mmHg/s) -12,054 – 1809 -11,420– 950 -13,531 – 846 -10,943 – 991 0.21
Tau (ms) 5.1 – 0.1 4.9 – 0.2 5.6 – 0.2 6.3 – 0.4{,* 0.048
PRSW 83 – 9 84– 6 70 – 9 49 – 7{ 0.22
EES (mmHg/ll) 7.4 – 0.6 7.3 – 1.4 4.0 – 0.8 2.3 – 0.3{ 0.73
EDPVR (mmHg/ll) 0.22 – 0.03 0.18– 0.02 0.16 – 0.02 0.19 – 0.02 0.56
HR (bpm) 576 – 8 614– 12 528 – 9{ 530 – 14{ 1.00
Invasive hemodynamic measurements revealed increased systolic dysfunction in sGCa1-/-CM compared with WT mice after 12 weeks of
DOX administration.
Multiplicity-adjusted p-values for comparison between WT + DOX and sGCa1-/-CM + DOX are reported. {p < 0.05 versus saline and
*p< 0.05 versus WT + doxorubicin.
bpm, beats per minute; DOX, doxorubicin; dP/dtmax, maximum first derivative of developed LV pressure; dP/dtmin, minimum first derivative
of developed LV pressure; Ea, arterial elastance; EDPVR, end-diastolic pressure volume relationship; EDV, end-diastolic volume; EES, end-
systolic elastance; EF, ejection fraction; ESV, end-systolic volume; HR, heart rate; LV, left ventricular; MAP, mean arterial pressure; PED, end-
diastolic pressure; PES, end-systolic pressure; PRSW, preload recruitable stroke work; sGC, soluble guanylate cyclase; sGCa1
-/-CM, mice with
cardiomyocyte-specific deletion of exon 6 of the sGCa1 allele; Tau, time constant for isovolumic relaxation; WT, wild-type.
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To determine whether reduced sGC activity contributes
to the development of doxorubicin-induced cardiotoxicity,
doxorubicin was administered to mice with a cardiomyocyte-
specific deficiency in sGCa1. After 12 weeks of doxorubicin
treatment, LV systolic dysfunction was more pronounced in
sGCa1-/-CM than in WT mice. Similarly, mice with induced
expression of a dominant negative mutated sGCa1
(DNsGCa1tg/+) displayed greater LV systolic dysfunction
and remodeling than WT mice after 12 weeks of doxorubicin
treatment. Together, these data reveal a protective role for
sGC against doxorubicin-induced cardiotoxicity.
FIG. 3. Greater DOX-induced LV dysfunction and di-
latation in DNsGCa1tg/+ than in WT mice. After 8 weeks
of DOX treatment, LVIDES and LVIDED were increased (A,
B) and FS decreased (C) in DNsGCa1tg/+, but not in WT,
mice (n = 20 each). After 12 weeks of DOX administration,
systolic dysfunction and dilatation were more pronounced in
DNsGCa1tg/+ than in WT mice. {p < 0.05 versus baseline
and *p < 0.05 versus WT (same time point). DNsGCa1tg/+,
mice with cardiomyocyte-specific expression of a dominant
negative mutation of sGCa1; LVIDES, left ventricular end-
systolic internal diameter; LVIDED, left ventricular end-
diastolic internal diameter; FS, fractional shortening.
FIG. 4. Attenuated LV dysfunction in DOX-treated
DNsGCa1tg/+ mice after reversal of sGCa1 mutant ex-
pression. (A) Doxycycline was added to the diet of
DNsGCa1tg/+ and WT mice after 8 weeks of DOX treatment
to initiate reversal of sGCa1 mutant expression in
DNsGCa1tg/+ mice. LV function and dimensions were as-
sessed via TTE after 12 weeks of DOX treatment (T12 weeks)
and 4 weeks after halting treatment (T16 weeks). (B) After 12
weeks of DOX treatment and 4 weeks of doxycycline ad-
ministration (T12 weeks), DOX-induced systolic dysfunction
and remodeling were still greater in DNsGCa1tg/+ than in WT
mice (n= 28 and 21, respectively). However, 4 weeks after
cessation of DOX treatment (and 8 weeks of doxycycline
administration), systolic function and dilatation had further
deteriorated in WT mice, but improved in DNsGCa1tg/+ mice.
{p< 0.05 versus 12 weeks and *p< 0.05 versus WT (same
time point). TTE, transthoracic echocardiography.
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Furthermore, we wanted to explore whether restoring sGC
activity could attenuate established cardiac dysfunction.
Since DNsGCa1tg/+ mice displayed LV dysfunction and re-
modeling after 8 weeks of doxorubicin administration,
whereas WT mice did not, the impact of restoring cardiac
sGC activity on doxorubicin-induced cardiotoxicity could be
evaluated by initiating reversal of sGCa1 mutant expression
in DNsGCa1tg/+mice at this time point. Halting expression of
mutated sGCa1 in DNsGCa1tg/+ mice after 8 weeks of
doxorubicin administration, resulting in restored sGC activ-
ity, eventually reduced LV dysfunction. Four weeks after
halting doxorubicin treatment, cardiac function was even less
impaired in DNsGCa1tg/+ mice than in WT animals.
It is possible that mechanisms to compensate for reduced
cardiac sGC activity are triggered in the DNsGCa1tg/+mouse
model. When expression of mutated sGCa1 is halted in these
DNsGCa1tg/+ mice, the resulting increase in sGC activity in
combination with potential compensatory mechanisms could
lead to enhanced cGMP signaling in comparison with WT
mice and may contribute to improvement of cardiac function
beyond the level observed in doxorubicin-treated WT mice.
Despite the observation that doxorubicin-induced cardiac
dysfunction was greater in sGCa1-/-CM and DNsGCa1tg/+
mice than in WT littermates, heart weights were similar in
doxorubicin-treated sGCa1-deficient and WT mice. In ad-
dition, cardiac Bcl-2 and Bax mRNA expression and car-
diomyocyte apoptosis did not differ between DNsGCa1tg/+
and WT mice following 12 weeks of doxorubicin treatment.
These results indicate that the increased cardiac dysfunc-
tion in doxorubicin-treated sGCa1-deficient mice did not
result from a greater loss of cardiomyocytes. In addition,
cardiac fibrosis, inflammation, and vascular density did not
differ between sGCa1 mutant and WT mice following 12
weeks of doxorubicin administration.
We cannot exclude that the degree of cardiac fibrosis,
apoptosis, inflammation, or vascular density might differ at
earlier or later time points. In addition, the difference in car-
diac function between doxorubicin-treated sGCa1-deficient
andWT mice did not reflect an effect of sGCa1 deficiency on
blood pressure, which was similar in doxorubicin-treated
sGCa1-/-CM and WT mice.
Oxidative stress has been suggested to play a prominent
role in doxorubicin-associated cardiotoxicity. In mice over-
expressing endothelial NO synthase (NOS3), doxorubicin-
induced cardiotoxicity was greater than in WT mice due to
abundant ROS production resulting from NOS3-mediated
FIG. 5. Increased DOX-
induced reactive oxygen
species production in sGCa1-
deficient hearts. (A) DCF
fluorescence, and thus re-
active oxygen species pro-
duction, was greater in
cardiomyocytes isolated from
sGCa1-/- than from WT mice
after in vitro exposure to
DOX (50lM for 3 h, average
of three independent experi-
ments). Fluorescence inten-
sity was normalized to protein
concentration and expressed
relative to levels in untreated
cardiomyocytes (i.e., without
DOX). (B) In addition, immu-
noblotting and densitometric
analysis revealed higher levels
of tyrosine nitration in
sGCa1-/- than WT hearts 24 h
after DOX administration
(20mg/kg IP). (C) Similarly,
more MDA-protein adducts
were observed in DNsGCa1tg/+
than WT hearts after 12
weeks of DOX administra-
tion. Immunoblotting for
Gapdh allowed to control for
sample variability. *p < 0.05
versus WT. DCF, 2¢,7¢-
Dichlorofluorescein; MDA,
malondialdehyde; 3-NT, 3-
nitrotyrosine.
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reduction of doxorubicin (34). We also observed increased
doxorubicin-induced ROS production in sGCa1-deficient
cardiomyocytes and greater oxidative stress levels in sGCa1-
deficient hearts after in vivo exposure to doxorubicin.
It is possible that the more pronounced doxorubicin-
induced oxidative stress in sGCa1-deficient cardiomyocytes
leads to greater contractile impairment. Oxidative stress can
alter expression, phosphorylation, or function of calcium
regulatory proteins such as sarcoplasmic reticulum calcium
ATPase 2A and ryanodine receptor 2 (1, 25, 54). Oxidative
stress also induces structural modifications of sarcomeric
proteins and disrupts mitochondrial function in cardiomyo-
cytes (44). Additional studies are required to evaluate whe-
ther increased oxidative stress levels in sGCa1-deficient
cardiomyocytes result in greater contractile impairment and,
if so, which mechanisms are involved.
Further support for a protective role of NO-sGC-cGMP
signaling in doxorubicin-induced cardiotoxicity was previ-
ously provided by the observation that supplementing dietary
nitrate reduced doxorubicin-induced cardiotoxicity (57). This
cardioprotection was associated with a decrease in ROS
generation, lipid peroxidation, and mitochondrial respiratory
chain damage (57).
In addition, pharmacological inhibition of the cGMP-
catabolizing enzyme, phosphodiesterase type 5 (PDE5), with
sildenafil or tadalafil attenuated doxorubicin-associated car-
diotoxicity in mice (17, 24). These PDE5 inhibitors reduced
doxorubicin-induced oxidative stress, disruption of the
mitochondrial membrane potential, apoptosis, and deple-
tion of prosurvival proteins in the heart (17, 24). Because
the ability of PDE5 inhibitors to augment cGMP levels is
inherently limited by cGMP synthesis, strategies designed
to enhance cGMP synthesis may be more effective in pre-
venting doxorubicin-induced cardiotoxicity. Nitroglycerin
and related NO donors are currently used to treat various
cardiovascular diseases. However, nitrates produce off-
target (cGMP-independent) effects and induce tolerance.
As many beneficial effects of NO are mediated through
sGC, pharmacological agents directly targeting sGC could
represent a novel mechanism-based approach to limit cardi-
otoxicity in patients undergoing doxorubicin-based chemo-
therapy. The therapeutic potential of targeting sGC to prevent
or even reverse doxorubicin-induced cardiotoxicity is sup-
ported by the observation that doxorubicin-induced LV
dysfunction in DNsGCa1tg/+ mice is attenuated by removing
inhibition of sGC activity. Future studies exploring the
therapeutic potential of sGC agonists for the treatment of
cardiotoxicity associated with doxorubicin treatment are
warranted.
In conclusion, doxorubicin administration reduces cardiac
sGC activity in mice, potentially via oxidative modification
of the enzyme. Our studies in two genetically modifiedmouse
models of cardiac sGCa1 deficiency demonstrate that re-
duced cardiac sGC activity contributes to the development of
doxorubicin-induced cardiotoxicity, identifying sGC as a
plausible therapeutic target to treat this devastating side ef-
fect of anthracycline-based chemotherapy. Carefully de-
signed preclinical studies with pharmacological sGC agonists
are required to test whether these drugs may provide an ad-
ditional tool to cardiologists and oncologists for preventing
chronic cardiomyopathy and heart failure in doxorubicin-
treated patients.
Materials and Methods
Experimental animals
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of La-
boratory Animals of the National Institutes of Health.
Housing and all procedures involving experimental animals
were approved by the Institutional Animal Care and Use
Committees of Massachusetts General Hospital (Sub-
committee on Research Animal Care).
Cardiomyocyte-specific sGCa1-/-CM mice were generated
by crossingmice in which exon 6 of the sGCa1 allele is flanked
by two LoxP sites [sGCa1fl/fl, generated by our group (7)] with
mice expressing Cre recombinase under the control of an a-
myosin heavy chain promoter (aMHC-Cre+/-). In cardiomyo-
cytes of sGCa1fl/flaMHC-Cre+/- offspring (referred to as
sGCa1-/-CM mice), Cre recombinase induces deletion of exon
6, encoding a portion of the catalytic domain of sGCa1 required
for enzyme activity. These mice were maintained on a C57BL/
6J background (The Jackson Laboratory, Farmington, CT) and
sGCa1fl/flaMHC-Cre-/- littermates served as WT controls.
To establish the DNsGCa1tg/+ mouse model, a first mouse
line was generated in which expression of a mutated sGCa1-
encoding gene is driven by a doxycycline-responsive pro-
moter element (tetracycline operator [TetO]). The dominant
negative point mutation introduced into the sGCa1-encoding
gene results in an amino acid change in the catalytic region of
sGCa1 (D529A, Asp to Ala) (55). Following implantation of
microinjected FVB zygotes into a pseudopregnant Swiss
foster mother, offspring were genotyped, and transgenic
founders were backcrossed for >6 generations onto a C57BL/
6N background (Taconic, Hudson, NY).
This mouse line was crossed with a second mouse line
expressing the gene encoding a tetracycline transactivator
(tTA) protein under the control of an aMHC promoter, kindly
provided by Dr. D.A. Dichek (University of Washington
Medical Center, Seattle, WA), and maintained on a C57BL/
6N background (Taconic, Hudson, NY).
When doxycycline is removed from the diet (doxycycline-
containing chow, 200 mg/kg; Harlan Laboratories,
Huntingdon, United Kingdom) of dual heterozygous TetO-
DNsGCa1+/-aMHC-tTA+/- offspring (referred to as DNsGCa1tg/+
mice), doxycycline-mediated repression of transcriptional
activation is abolished (Tet-Off system), and tTA binds to
and activates transcription from the TetO promoter element,
inducing expression of the sGCa1 mutant specifically in
cardiomyocytes. DNsGCa1tg/+ mice and their WT controls
(TetO-DNsGCa1-/-aMHC-tTA-/- littermates) were conceived
and raised in the presence of doxycycline. When the mice
were 4–6 weeks old, doxycycline was withdrawn, and 4
weeks later, mice were used for experiments.
Doxorubicin treatment regimen
For acute studies, 8-week-old C57BL/6J mice (The Jack-
son Laboratory) were injected with a single dose of doxo-
rubicin (20mg/kg IP, using a 2mg/ml stock of doxorubicin
hydrochloride obtained from Pfizer, NewYork, NY) or saline
and sacrificed 24 h later. A subset of these mice were pro-
vided with the radical scavenger, tempol (1-oxyl-2,2,6,6-
tetramethyl-4-hydroxypiperidine; Thermo Fisher Scientific,
Waltham, MA), via drinking water (1mM) 4 days before
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doxorubicin or saline treatment and via gavage (30mg/kg)
1 h before treatment.
For chronic studies, 8–12-week-old male and female
DNsGCa1tg/+, sGCa1-/-CM, and WT mice were administered a
lowdose of doxorubicin for 12weeks (2mg/kg IP, onceweekly).
Transthoracic echocardiography
To measure LV systolic function and dimensions,
sGCa1-/-CM mice were lightly sedated (ketamine, 100mg/kg,
IP) and echocardiography was performed using a 13MHz
ultrasound probe (Vivid 7; GE Healthcare, Wilmington,
MA). DNsGCa1tg/+ mice were sedated with 1.5% isoflurane
and echocardiograms were obtained using an MS400 trans-
ducer on a Vevo 2100 scanner (VisualSonics, Inc., Toronto,
Canada). LVIDED and LVIDES, interventricular septal
thickness at end-diastole, LV posterior wall thickness at end-
diastole, and HR were measured and FS calculated, as pre-
viously described (39).
Invasive hemodynamic measurements
Mice were anesthetized by IP injection with ketamine
(120mg/kg), fentanyl (90lg/kg), and rocuronium (10mg/kg),
intubated, and mechanically ventilated (FiO2= 1, 10ll/g,
120 breaths per minute). A fluid-filled catheter was introduced
into the carotid artery to record arterial blood pressure and HR.
After thoracotomy, a pressure–volume conductance catheter
(PVR-1030; Millar Instruments, Houston, TX) was introduced
through the apex into the LV, as described previously (19).
LV end-systolic and end-diastolic volumes and LV pres-
sures were measured, and EF, arterial elastance, the maxi-
mum and minimum first derivative of developed LV pressure
(dP/dtmax and dP/dtmin), and the time constant for isovolumic
relaxation (Tau) were calculated. The preload recruitable
stroke work, end-systolic elastance, and end-diastolic pres-
sure–volume relationship were obtained by transiently oc-
cluding the inferior vena cava. All parameters were measured
using LabChart (ADInstruments, Colorado Springs, CO).
sGC activity measurements
sGC enzyme activity was measured as described previously
(7). Cardiac tissues were homogenized and supernatants (con-
taining 50lg of protein) were incubated for 10min at 37C in a
reaction mixture with DETA-NO (1mmol/l) or BAY 58-2667
(100lmol/l). cGMP in the reactionmixture wasmeasured using
a commercial radioimmunoassay (Cayman Chemical, Ann
Arbor,MI). sGC enzyme activitywas expressed as picomoles of
cGMP produced per minute per milligram of protein in cardiac
extract supernatant, normalized to the contemporaneous control
group (saline-treated mice when sGC activity was measured in
doxorubicin-treated mice and WT mice when sGC activity was
measured in sGCa1-deficient mice).
Histological and immunoblot analysis
Immunohistochemistry was performed as described pre-
viously (52). Images were obtained using an Axiovert 200M
imaging microscope (Zeiss, Oberkochen, Germany). To as-
sess the degree of cardiac fibrosis, the area of collagen de-
position was traced on Sirius red-stained tissue sections using
circularly polarized light, allowing evaluation of tightly
packed, red birefringent collagen and thin, loosely assem-
bled, green birefringent collagen. The degree of fibrosis was
expressed as the area of red or green birefringent collagen
relative to the area of the examined LV tissue area.
Apoptotic cardiomyocytes were detected by labeling DNA
strand breaks using TUNEL (ApopTag; Millipore, Billerica,
MA), according to the manufacturer’s instructions. The index
of apoptosis was determined by dividing the number of im-
munolabeled cardiomyocyte nuclei by the area of the ex-
amined LV tissue area.
Vascular density was analyzed on BS1-lectin-stained
tissue sections (Sigma-Aldrich, St.-Louis, MO) by dividing
the number of positively stained small blood vessels by the
number of cardiomyocyte nuclei.
Mouse cardiac tissue was homogenized in RIPA buffer
containing Halt protease and phosphatase inhibitors (Thermo
Fisher Scientific). Homogenates were transferred to Eppendorf
tubes, incubated on ice for 20min, centrifuged at 14,000 g for
10min, and supernatants collected. Proteins were separated by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis,
transferred to Immobilon-FL polyvinylidene difluoride mem-
branes (Millipore) by semidry electroblotting, blocked for 1 h in
Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE),
and probed overnight with antibodies specific for sGCa1 (Ab-
cam, Cambridge,MA), sGCb1 (Sigma-Aldrich), 3-nitrotyrosine
(3-NT; Millipore), or glyceraldehyde-3-phosphate dehydroge-
nase (Cell Signaling Technology, Danvers, MA). Bound
fluorophore-coupled secondary antibodies were visualized us-
ing the Odyssey system (LI-COR Biosciences).
For MDA immunoblotting, proteins were transferred to a
nitrocellulose membrane, which was blocked for 1 h in 5%
nonfat milk. Bound primary antibody (Millipore) was de-
tected using a horseradish peroxidase-conjugated secondary
antibody (Dako, Heverlee, Belgium) and visualized using
ECL Plus Western blotting detection reagents (GE Health-
care, Buckinghamshire, United Kingdom).
For all immunoblots, densitometric analysis was per-
formed using ImageJ software (NIH, whole lane densitom-
etry for 3-NT and MDA immunoblots).
Quantitative real-time polymerase chain reaction
Cardiac expression of genes involved in fibrosis and apo-
ptosis was measured using quantitative real-time polymerase
chain reaction (TaqMan or SYBR green PCR master mix;
Life Technologies, Carlsbad, CA). Relative mRNA levels
were analyzed using the Livak method (29).
Measurements of DCF fluorescence
Cardiomyocytes were isolated from global sGCa1-/- mice
and WT littermates by Langendorff perfusion, as previously
described (27). After plating cardiomyocytes onto laminin-
coated plates, the cells were incubated with 50lmol/l
doxorubicin (Sigma-Aldrich) for 3 h, washed with
phosphate-buffered saline, and lysed by adding 100 ll T-PER
(Thermo Fisher Scientific). Next, 140ll of 50lM CM-H-
2DCFDA (Life Technologies) was added to 10ll cell lysate
(96-well plate). Following incubation at 25C for 10min in
the dark, DCF fluorescence was measured using a spectro-
fluorometer (BMG Labtech, Ortenberg, Germany), as previ-
ously described (16). Fluorescence intensity was normalized to
protein concentration and expressed relative to levels in un-
treated cardiomyocytes (i.e., without doxorubicin).
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Statistical analysis
Values are presented as mean – standard error of the mean.
When comparing two groups, normal distribution of the data
was assessed using the Shapiro–Wilk test, and an unpaired two-
tailed t-test (parametric) or a Mann–Whitney test (nonpara-
metric) was used. Serial echocardiographic data were analyzed
by two-way analysis of variance (ANOVA) and Sidak’s mul-
tiple comparisons test. For these experiments, the required
samples sizes were calculated to yield statistical power of
‡0.80 (a= 0.05). Analysis of pressure–volume measurements
was performed via one-way ANOVA and Sidak’s multiple
comparisons test (when passed the Shapiro–Wilk normality
test) or the Kruskal–Wallis test and Dunn’s multiple compar-
isons test (when failed the Shapiro–Wilk normality test).
Survival was analyzed via the Kaplan–Meier method.
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Abbreviations Used
3-NT¼ 3-nitrotyrosine
ANOVA¼ analysis of variance
Bax¼B cell lymphoma 2-associated X protein
Bcl-2¼B cell lymphoma 2
bpm¼ beats per minute
cGMP¼ cyclic guanosine 3¢,5¢-monophosphate
CM-H2DCFDA¼ chloromethyl derivate of
2¢,7¢-dichlorodihydrofluorescein
diacetate
CO¼ carbon monoxide
CTGF¼ connective tissue growth factor
DCF¼ 2¢,7¢-dichlorofluorescein
DETA-NO¼ diethylenetriamine NONOate
DNsGCa1tg/+¼mice with cardiomyocyte-specific
expression of a dominant negative
mutation of sGCa1
DOX¼ doxorubicin
dP/dtmax¼maximum first derivative of developed
LV pressure
dP/dtmin¼minimum first derivative of developed
LV pressure
Ea¼ arterial elastance
EDPVR¼ end-diastolic pressure volume relationship
EDV¼ end-diastolic volume
EES¼ end-systolic elastance
EF¼ ejection fraction
ESV¼ end-systolic volume
FS¼ fractional shortening
Gapdh¼ glyceraldehyde-3¢-phosphate
dehydrogenase
HR¼ heart rate
IP¼ intraperitoneal
IVSED¼ interventricular septal thickness
at end-diastole
LV¼ left ventricular
LVIDED¼ left ventricular end-diastolic internal
diameter
LVIDES¼ left ventricular end-systolic internal
diameter
LVPWED¼ left ventricular posterior wall thickness
at end-diastole
MAP¼mean arterial pressure
MDA¼malondialdehyde
MHC¼myosin heavy chain
NO¼ nitric oxide
NOS3¼ endothelial nitric oxide synthase
PCR¼ polymerase chain reaction
PDE5¼ phosphodiesterase type 5
PED¼ end-diastolic pressure
PES¼ end-systolic pressure
PRSW¼ preload recruitable stroke work
ROS¼ reactive oxygen species
sGC¼ soluble guanylate cyclase
sGCa1-/-CM¼mice with cardiomyocyte-specific
deletion of exon 6 of the sGCa1 allele
Tau¼ time constant for isovolumic relaxation
tetO¼ tetracycline operator
TGF-b1¼ transforming growth factor-b1
tTA¼ tetracycline transactivator
TTE¼ transthoracic echocardiography
WT¼wild-type
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